NDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUTOPAR (ritodrine hydrochloride) is an oral small-molecule beta-2 adrenergic agonist used to manage premature labor and extend pregnancy duration. The drug works by relaxing uterine smooth muscle, reducing uterine contractions and delaying delivery. It represents a niche therapeutic option in obstetrics with limited modern competition.
LOE Approaching
Product is in late-stage lifecycle with low linked job volume, suggesting a mature brand team focused on margin protection rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YUTOPAR offers limited career growth due to zero linked job openings and LOE-approaching status, making it a consolidation or maintenance-focused role. Opportunities exist primarily in market access, generic defense, and operational efficiency rather than innovation or expansion.
Brand ManagerCommercial Operations Manager
Worked on YUTOPAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.